Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase 2 Recruiting 40 enrolled Australasian Gastro-Intestinal Trials Group AstraZeneca · collab Wayne Elphinstone Research Fund · collab

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.

Timeline

Start: 2024-09-23
Primary completion: 2026-08
Completion: 2028-08

Publications

Nilsen O, Senko C, Collins A, Tomkins N, Buckley D, Weickhardt A, Tebbutt N. Triple M Syndrome Associated With Concurrent Durvalumab and Olaparib Therapy in Metastatic Cholangiocarcinoma: A Case Report. Case Rep Oncol Med. 2026 Jun 22;2026:1318038. doi: 10.1155/crom/1318038. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	Intravenous
Subject	Olaparib	Small molecule	300 mg	Oral

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Summary

Timeline

Publications

Drugs

Indications